Adjuvant therapy for breast cancer.

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Significant advancements in adjuvant hormonal and chemotherapeutic treatments for breast cancer over the past 30 years.
• Availability of cytotoxic agents (anthracyclines, taxanes, CMF) and hormonal agents (aromatase inhibitors).
• Established survival benefits for lymph node-positive breast cancer patients receiving adjuvant therapy.

Purpose of the Study:

• To review the current landscape of adjuvant hormonal and chemotherapeutic treatments for breast cancer.
• To highlight the efficacy of newer agents like aromatase inhibitors and taxane-containing regimens.
• To discuss the ongoing research into personalized medicine and molecular markers for treatment selection.

Main Methods:

• Review of clinical data and established treatment protocols for breast cancer adjuvant therapy.
• Comparison of efficacy between different chemotherapy regimens (e.g., anthracyclines vs. CMF, taxane inclusion).
• Evaluation of hormonal therapies, including tamoxifen and aromatase inhibitors (e.g., letrozole).

Main Results:

• Aromatase inhibitors are superior to tamoxifen in postmenopausal women with hormone receptor-positive breast cancer.
• Extended letrozole therapy improves survival and reduces late relapses after initial tamoxifen treatment.
• Anthracycline-based chemotherapy, especially with taxanes, shows improved efficacy over CMF; dose optimization is crucial.

Conclusions:

• While effective adjuvant regimens exist, no single treatment is universally superior.
• Personalized treatment selection based on molecular markers is a key area of current research.
• Trastuzumab incorporation into adjuvant chemotherapy for HER-2 amplified tumors is a promising future direction.